Relationship between red blood cell thiopurine methyltransferase activity and myelotoxicity in dogs receiving azathioprine

Journal of Veterinary Internal Medicine

Volumn 18, Issue 3, 2004, Pages 339-345

  Rodriguez, Damon B ^a,c   Mackin, Andrew ^a   Easley, Roger ^a   Boyle, Carolyn R ^a   Hou, Weiying ^b   Langston, Cory ^a   Walsh, Amy M ^a   Province, Michael A ^b   McLeod, Howard L ^b  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Cincinnati Animal Referral and Emergency Center   (United States)

Author keywords

Myelosuppression; Neutropenia; Population survey; Toxicity

Indexed keywords

AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INDICATION; DRUG SAFETY; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; MALE; NEUTROPENIA; NONHUMAN;

ANIMALS; AZATHIOPRINE; DOGS; ERYTHROCYTES; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLTRANSFERASES; NEUTROPENIA; NEUTROPHILS;

ANIMALIA; CANIS FAMILIARIS;

EID: 2942538527     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2004)18<339:RBRBCT>2.0.CO;2     Document Type: Article

References (44)

1. White SD, Rosser EJ, Ihrke PJ, Stannard AA. Bullous pemphigoid in a dog: Treatment with six-mercaptopurine. J Am Vet Med Assoc 1984;185:683-686.
2. Willard MD. Inflammatory bowel disease: Perspectives on therapy. J Am Anim Hosp Assoc 1992;28:27-32.
3. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995;131:193-197.
4. Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopuine metabolism in Crohn's disease: Correlation with efficacy and toxicity. Gut 1996;39:401-406.
5. Rinkardt NE, Kruth SA. Azathioprine-induced bone marrow toxicity in four dogs. Can Vet J 1996;37:612-613.
6. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987;41:18-25.
7. Chan GLC, Erdmann GR, Gruber SA, et al. Azathioprine metabolism: Pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990;30:358-363.
8. Sebbag L, Boucher P, Davelu P, et al. Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients. Transplantation 2000;69:1524-1527.
9. Elion GB. Biochemistry and pharmacology of purine analogues. Fed Proc 1967;26:898-904.
10. Rees AJ, Lockwood CM. Immunosuppressive drugs in clinical practice. In: Lachman PJ, Peters DK, eds. Clinical Aspects of Immunology, 4th ed. London: Blackwell; 1982:507-564.
11. Ogilvie GK, Felsburg PJ, Harris CW. Short-term effect of cyclophosphamide and azathioprine on selected aspects of the canine blastogenic response. Vet Immunol Immunopathol 1988;18:119-127.
12. Stolk JN, Boerbooms AMT, De Abreu RA, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1858-1866.
13. Beale KM. Azathioprine for treatment of immune-mediated diseases of dogs and cats. J Am Vet Med Assoc 1988;192:1316-1318.
14. Houston DM, Taylor JA. Acute pancreatitis and bone marrow suppression in a dog given azathioprine. Can Vet J 1991;32:496-497.
15. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001;7:181-189.
16. Lennard L. Clinical implications of thiopurine methyltransferase - Optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998;20:527-531.
17. Otterness DM, Keith RA, Weinshilboum RM. Thiopurine methyltransferase: Mouse kidney and liver assay conditions, biochemical properties and strain variation. Biochem Pharmacol 1985;34:3823-3830.
18. Weinshilboum RM, Raymond FA, Pamzino PA. Human erythrocyte thiopurine methyltransferase: Radiochemical micro assay and biochemical properties. Clin Chim Acta 1978;85:323-333.
19. Woodson LC, Dunnette JH, Weinshilboum RM. Pharmacogenetics of human thiopurine methyltransferase: Kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther 1982;22:174-181.
20. Szumlanski CL, Hinchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics - Biochemical properties, liver-erythrocyte correlation and presence of isoenzymes. Pharmacogenetics 1992;2:148-159.
21. Lennard L, Lilleyman JS. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monit 1996;18:328-334.
22. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:1743-1750.
23. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-662.
24. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in caucasians. Am J Hum Genet 1996;58:694-702.
25. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000;14:567-572.
26. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716-718.
27. Andersen JB, Szumlanski C, Weinshilboum RM, Schmiegelow K. Pharmacokinetics, dose adjustments and 6-mercaptopuine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 1998;87:108-111.
28. Krynetski E, Schuetz JD, Galpin AJ, et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A 1995;92:949-953.
29. Tavadia SMB, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: A pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000;42:628-632.
30. McLeod HL, Relling MV, Liu Q, et al. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995;85:1897-1902.
31. Foster AP, Shaw SE, Duley JA, et al. Demonstration of thiopurine methyltransferase activity in the erythrocytes of cats. J Vet Intern Med 2000;14:552-554.
32. White SD, Rosychuk RAW, Outerbridge CA, et al. Thiopurine methyltransferase in red blood cells of dogs, cats, and horses. J Vet Intern Med 2000;14:499-502.
33. Harvey JW. Atlas of Veterinary Hematology. Philadelphia, PA: WB Saunders; 2001:113-123.
34. MacLean CJ, Morton NE, Elston RC, Yee S. Skewness in commingled distributions. Biometrics 1976;32:695-699.
35. Salavaggione OE, Kidd L, Prondzinski JL, et al. Canine red blood cell thiopurine S-methyltransferase: Companion animal pharmacogenetics. Pharmacogenetics 2002;12:713-724.
36. Kidd L, Trepanier L, Salavagginone E, et al. Azathioprine metabolism in dogs: Implications for drug dosing. Proceedings of the 20th ACVIM Forum, Dallas, TX, 2002.
37. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002;51:143-146.
38. Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002;111:360-367.
39. Fraser JK, Meyers H, Henderson JF, et al. Individual variation in inosine triphosphate accumulation in human erythrocytes. Clin Biochem 1975;8:353-364.
40. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983;33:591-602.
41. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;50:663-672.
42. Giger U, Werner LL, Millichamp NJ, et al. Sulfadiazine-induced allergy in six Doberman Pinschers. J Am Vet Med Assoc 1985;186:479-484.
43. Trepanier LA, Cribb AE, Danhof RS, et al. Clinical and immunologic findings in 45 dogs with sulfonamide-associated hypersensitivity. Proceedings of the 20th ACVIM Forum, Dallas, TX, 2002.
44. McLeod HL, Lin JS, Scott EP, et al. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994;55:15-20.